{"entity":{"id":"nct04718883","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells in mantle cell lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.","summary":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT04718883 by Shanghai Ming Ju Biotechnology Co., Ltd., with 59 participants enrolled, started 2021-01-13 and due to reach its primary completion in 2023-10-25. Interventions recorded: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04718883","url":"https://clinicaltrials.gov/study/NCT04718883"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["jw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04718883","phase":"2","setting":"A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","enrolled":59,"outcomes":[]},"route":"/trials/nct04718883/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"company":[{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/"}]}}